FEMYHIGH SIGNALFINANCIAL10-K

FEMY executed a major equity raise that more than doubled outstanding shares while dramatically improving its balance sheet and liquidity position.

The outstanding share count more than doubled from 27.1M to 60.4M shares, indicating a significant dilutive equity financing that raised substantial capital. This financing transformed the company's financial position by tripling cash reserves and converting short-term debt obligations into long-term financing, buying critical time for product development and commercialization efforts.

Comparing 2026-03-31 vs 2025-03-27View on EDGAR →
FINANCIAL ANALYSIS

FEMY's financial position strengthened dramatically through what appears to be a major equity raise, with cash increasing 168% to $9.3M and stockholders' equity rising 155% to $5.9M, while current liabilities dropped 58% indicating debt restructuring or paydown. Revenue grew a solid 41% to $2.3M and inventory nearly doubled, suggesting increased production capacity, though interest expense spiked over 1000% reflecting higher debt levels before the financing. Overall, the company appears to have successfully addressed near-term liquidity concerns through dilutive but necessary capital raising.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+1128.4%
$13K→$165K

Interest expense surged 1128.4% — significant debt increase or rising rates materially impacting earnings.

Cash & Equivalents
Balance Sheet
+168.5%
$3.5M→$9.3M

Cash position surged 168.5% — strong cash generation or capital raise providing significant financial cushion.

Stockholders Equity
Balance Sheet
+154.7%
$2.3M→$5.9M

Equity base grew 154.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Assets
Balance Sheet
+105.1%
$8.0M→$16.5M

Current assets grew 105.1% — improving short-term liquidity or inventory/receivables build.

Inventory
Balance Sheet
+88.4%
$3.0M→$5.7M

Inventory surged 88.4% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Share Buybacks
Cash Flow
-73.6%
$230K→$61K

Buyback activity reduced 73.6% — capital being redeployed elsewhere or cash conservation underway.

Total Assets
Balance Sheet
+66.5%
$12.4M→$20.7M

Asset base grew 66.5% — expansion through organic growth, acquisitions, or capital deployment.

Current Liabilities
Balance Sheet
-57.6%
$8.6M→$3.6M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
+46.5%
$10.1M→$14.9M

Liabilities grew 46.5% — significant increase in debt or obligations, assess impact on financial flexibility.

Revenue
P&L
+40.8%
$1.6M→$2.3M

Strong top-line growth of 40.8% — accelerating demand or successful expansion into new markets.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-03-27
ADDED
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.
As of March 30, 2026, there were 60,390,686 shares of the registrant s $0.001 par value common stock outstanding.
These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include, but are not limited to, statements concerning: our ability to obtain additional financing to fund commercialization of our products and fund our operations; our ability to obtain additional financing to fund the U.S.
product candidate FemBloc permanent birth control; our ability to obtain U.S.
+7 more — sign up free →
REMOVED
As of March 26, 2025, there were 27,149,971 shares of the registrant s $0.001 par value common stock outstanding.
Forward-looking statements include, but are not limited to, statements concerning: our ability to obtain additional financing to fund the clinical development and commercialization of our product candidate FemBloc permanent birth control, if approved for sale, approved products and fund our operations; our ability to pay our convertible notes due November 2025 when due, if not converted into common stock; our ability to obtain U.S.
or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States and international markets; the timing or likelihood of regulatory filings and approvals or clearances; our ability to establish and maintain intellectual property protection for our products and product candidate and our ability to avoid claims of infringement; and the volatility of the trading price of our common stock.
The FDA may not allow us to continue the ongoing pivotal trial for FemBloc Premarket approval (PMA) due to safety concerns.
We are substantially dependent on the FDA s permission to market our FemBloc system.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →